Cefiderocol Compared With Meropenem for Nosocomial Pneumonia Treatmenthttps://www.empr.com/home/news/cefiderocol-compared-with-meropenem-for-nosocomial-pneumonia-treatment/
Cefiderocol Now Available in the U.Shttps://www.idse.net/Bacterial-Infections/Article/02-20/Cefiderocol-Now-Available-in-the-U.S/57395
Cefiderocol for Urinary Infections Set for FDA Advisory Review | Medpage Todayhttps://www.medpagetoday.com/infectiousdisease/generalinfectiousdisease/82754
FDA Advisory Committee Backs Cefiderocol Efficacy for cUTI 14-2https://www.contagionlive.com/news/fda-advisory-committee-backs-cefiderocol-efficacy-for-cuti-142
FDA Panel Recommends Cefiderocol for Complicated UTIhttps://www.medscape.com/viewarticle/919979
FDA Panel Votes on Novel Antibiotic for Complicated UTI - MPRhttps://www.empr.com/home/news/fda-panel-votes-on-novel-antibiotic-for-complicated-uti/
Investigational antibiotic, Cefiderocol, receives U.S. FDA Advisory Committee recommendation for approval to treat complicated UTIs - Outbreak News Todayhttp://outbreaknewstoday.com/investigational-antibiotic-cefiderocol-receives-u-s-fda-advisory-committee-recommendation-for-approval-to-treat-complicated-utis-63891/
New Antibiotics Treat Select Resistant Infectionshttps://www.pharmacytimes.com/publications/health-system-edition/2020/May2020/new-antibiotics-treat-select-resistant-infections
Positive CHMP opinion for Shionogi's treatment of infections due to aerobic Gram-negative bacteria - Pharmafieldhttps://pharmafield.co.uk/pharma_news/positive-chmp-opinion-for-shionogis-treatment-of-infections-due-to-aerobic-gram-negative-bacteria/
Shionogi Announces Data Demonstrating Potent in Vitro Activity of Cefiderocol against the Most Critical Priority Gram-Negative Bacterial Pathogens - DutchNews.nlhttps://www.dutchnews.nl/news/businesswire/shionogi-announces-data-demonstrating-potent-in-vitro-activity-of-cefiderocol-against-the-most-critical-priority-gram-negative-bacterial-pathogens/
Shionogi announces data demonstrating potent in vitro activity of cefiderocol against the most critical priority gram-negative bacterial pathogens - PharmiWeb.comhttps://www.pharmiweb.com/press-release/2019-04-17/shionogi-announces-data-demonstrating-potent-in-vitro-activity-of-cefiderocol-against-the-most-critical-priority-gram-negative-bacterial-pathogens
Stewardship / Resistance Scan for Feb 25, 2020 | CIDRAPhttp://www.cidrap.umn.edu/news-perspective/2020/02/stewardship-resistance-scan-feb-25-2020
Stewardship / Resistance Scan for Oct 03, 2019 | CIDRAPhttp://www.cidrap.umn.edu/news-perspective/2019/10/stewardship-resistance-scan-oct-03-2019
Stewardship / Resistance Scan for Oct 17, 2019 | CIDRAPhttp://www.cidrap.umn.edu/news-perspective/2019/10/stewardship-resistance-scan-oct-17-2019
Two More Agents Bolster the Arsenal Against Gram-Negative Resistancehttps://www.contagionlive.com/publications/contagion/2019/december/two-more-agents-bolster-the-arsenal-against-gramnegative-resistance
U.S. FDA Advisory Committee Recommends Approval of Cefiderocol for Treatment of Complicated Urinary Tract Infections | Business Wirehttps://www.businesswire.com/news/home/20191016005916/en/U.S.-FDA-Advisory-Committee-Recommends-Approval-Cefiderocol
With Potent In Vitro Activity, Cefiderocol a Promising Option for Treating Resistancehttps://www.contagionlive.com/news/with-potent-in-vitro-activity-cefiderocol-a-promising-option-for-treating-resistance
[Full text] Designing A Pathogen-Focused Study To Address The High Unmet Medical N | IDRhttps://www.dovepress.com/designing-a-pathogen-focused-study-to-address-the-high-unmet-medical-n-peer-reviewed-fulltext-article-IDR

Showing topic